Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Abstract Text:

    robin de vriesRobin de Vries,simon daenenSimon Daenen,keith tolleyKeith Tolley,axel glasmacherAxel Glasmacher,archie prenticeArchie Prentice,sarah howellsSarah Howells,hariette christophersonHariette Christopherson,lolkje t w de jong-van den bergLolkje T W de Jong-van den Berg,maarten j postmaMaarten J Postma,

    BACKGROUND: Invasive fungal infections in neutropenic patients treated for haematological malignancies are associated with a high mortality rate and, therefore, require early treatment. As the diagnosis of invasive fungal infections is difficult, effective antifungal prophylaxis is desirable. So far, fluconazole has been the most commonly used. OBJECTIVE: To assess the cost effectiveness of itraconazole compared with both fluconazole and no prophylaxis for the prevention of invasive fungal infections in haematological patients, mean age 51 years, in Germany and The Netherlands. STUDY DESIGN: We designed a probabilistic decision model to fully incorporate the uncertainty associated with the risk estimates of acquiring an invasive fungal infection. These risk estimates were extracted from two meta-analyses, evaluating the effectiveness of fluconazole and itraconazole and no prophylaxis. The perspective of the analysis was that of the healthcare sector; only medical costs were taken into account. All costs were reported in euro, year 2004 values.Cost effectiveness was expressed as net costs per invasive fungal infection averted. No discounting was performed, as the model followed patients during their neutropenic period, which was assumed to be less than 1 year. RESULTS: According to our probabilistic decision model, the monetary benefits of averted healthcare exceed the costs of itraconazole prophylaxis under baseline assumptions (95% CI: from cost-saving to euro5000 per invasive fungal infection averted). Compared with fluconazole, itraconazole is estimated to be both more effective and more economically favourable, with a probability of almost 98%. CONCLUSIONS: In specific groups of neutropenic patients treated for haematological malignancies, itraconazole prophylaxis could potentially reduce overall healthcare expenditure, without harming effectiveness, in settings where fluconazole is common practice in the prophylaxis of invasive fungal infections.

    Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Publishing Authors By Initials

    r de vriesR de Vries,s daenenS Daenen,k tolleyK Tolley,a glasmacherA Glasmacher,a prenticeA Prentice,s howellsS Howells,h christophersonH Christopherson,lt de jong-van den bergLT de Jong-van den Berg,mj postmaMJ Postma,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: PharmacoEconomics

    VOLUME: 26

    Page Numbers: 75-90

    Journal Abbreviation:

    ISSN: 1170-7690

    DAY: 19

    MONTH: 12

    YEAR: 2008

    Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9212404

    Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.

    AFFILIATION: Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands.

    Country: New Zealand

    New Zealand Research PublicationNew Zealand Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Pharmacoeconomics

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News